Prime Medicine Full Year Earnings Report

Prime Medicine EPS Results

• Actual EPS: -$1.65
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: -$2.18

Prime Medicine Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Prime Medicine Announcement Details

• Quarter: Full Year
• Date: 3/7/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Prime Medicine (NASDAQ:PRME) is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations.

Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient. The company’s development pipeline has included programs for inherited disorders such as chronic granulomatous disease, as well as potential applications in immunology, oncology, and other therapeutic areas.

Founded in 2019, Prime Medicine is headquartered in Cambridge, Massachusetts. The company was established around Prime Editing technology developed by researchers including David R. Liu, a professor at Harvard University and the Broad Institute of MIT and Harvard. Prime Medicine’s activities are primarily centered on research, clinical development, and potential commercialization of gene-editing therapies.